Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies

Table 2 Longitudinal association of low-dose ASA use with all-cause and common subtype dementia incidence

	ESTHER, N = 5286						UK Biobank, N = 305,394
	All-cause dementia		Alzheimer’s disease		Vascular dementia		All-cause dementia		Alzheimer’s disease		Vascular dementia
	n_case	HR (95% CI)	n_case	HR (95% CI)	n_case	HR (95% CI)	n_case	HR (95% CI)	n_case	HR (95% CI)	n_case	HR (95% CI)
Simple model^a	476	0.93 (0.73, 1.18)	157	0.68 (0.43, 1.07)	182	1.00 (0.69, 1.45)	5,584	1.12 (1.05, 1.20)	2029	1.11 (0.99, 1.25)	1437	1.27 (1.12, 1.45)
IPTW model	476	1.01 (0.89, 1.14)	157	0.81 (0.64, 1.01)	182	1.19 (0.97, 1.46)	5,584	0.95 (0.92, 0.99)	2029	1.00 (0.94, 1.06)	1437	0.94 (0.88, 1.00)
IPTW model plus 5-year lag-time^b	409	0.93 (0.81, 1.08)	129	0.68 (0.51, 0.89)	158	1.23 (0.99, 1.53)	4,855	0.94 (0.90, 0.97)	1744	1.00 (0.94, 1.07)	1225	0.95 (0.88, 1.02)

Note: Statistically significant results are printed in bold
Abbreviations: IPTW, inverse probability of treatment weighting
^aSimple model was adjusted for age, sex, education, APOE genotypes, BMI, smoking status, alcohol consumption, physical activity, diabetes, hypertension, coronary heart disease, and depression
^bDementia cases, which happened within the first 5 years of follow-up were excluded, resulting in a total sample size of N=5,191

ISSN: 1758-9193